YSYS Biopharma Co., Ltd.

Nasdaq N/A


$ 0.94 $ -0.07 (-7.21 %)    

Friday, 10-May-2024 15:54:39 EDT
QQQ $ 443.37 $ -1.41 (-0.32 %)
DIA $ 393.96 $ -1.13 (-0.28 %)
SPY $ 520.66 $ -1.52 (-0.29 %)
TLT $ 90.76 $ 0.14 (0.16 %)
GLD $ 217.95 $ 0.11 (0.05 %)
$ 0.9001
$ 0.95
$ 0.00 x 0
$ 0.00 x 0
$ 0.94 - $ 0.95
$ 0.35 - $ 1.78
109,165
na
83.76M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ys-biopharma-granted-phase-i-clinical-trial-license-of-therapeutic-chronic-hepatitis-b-virus-vaccine

YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedica...

 chinese-biotech-ys-biopharmas-next-gen-rabies-vaccine-non-inferior-to-approved-competitor

YS Biopharma unveils interim results from Phase 3 trial of PIKA Rabies Vaccine, meeting primary endpoints. With accelerated imm...

 ys-biopharma-appoints-six-new-members-to-its-board-effective-february-13-2024-names-ajit-shetty-as-chairperson

The six new directors are: Dr. Yuntao Cui; Dr. Jin Wang; Mr. Henry Chen; Mr. Haitao Zhao; Mr. Pierson Yue Pan; and Ms. Brenda C...

 ys-biopharma-reports-h1-loss-per-shae-of-026-net-loss-243m

As of September 30, 2023, the company had cash and cash equivalents of RMB259.9 million ($36.2 million), compared with RMB370.4...

 ys-biopharma-responds-to-unauthorized-pr-regarding-extraordinary-general-meeting-says-yi-zhang-is-not-the-chairperson-and-does-not-have-any-authority-to-call-general-meeting-of-shareholders

The company said its filing on Form 6-K with the U.S. Securities and Exchange Commission on December 12, 2023 explicitly states...

 noble-capital-markets-initiates-coverage-on-ys-biopharma-co-with-outperform-rating-announces-price-target-of-525

Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and ...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION